MedTrace Logo

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

NCT06940154 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-04-27

No results posted yet for this study

Summary

This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation

Conditions

  • COPD Acute Exacerbation

Interventions

COMBINATION_PRODUCT

Rademikibart in prefilled syringe

Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.

DRUG

Matching placebo in prefilled syringe

Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.

Sponsors & Collaborators

  • Connect Biopharm LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-12
Primary Completion
2026-06-30
Completion
2026-07-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Georgia
  • Serbia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06940154 on ClinicalTrials.gov